Edwards Martin
- SEC CIK
- 0001640073
No open-market purchases or sales filed in the past year.
Current role at each company
- VRNA Verona Pharma plcDirectoras of Oct 8, 2025
- MORF Morphic Holding, Inc.Directoras of Aug 21, 2024
- INZY Inozyme Pharma, Inc.Directoras of Jun 20, 2024
- RETA Reata Pharmaceuticals IncDirectoras of Sep 26, 2023
- KALV KalVista Pharmaceuticals, Inc.Directoras of Oct 4, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Edwards Martin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VRNA Verona Pharma plc
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Edwards MartinDirector | SSale | −10.8K | $13.14 | −$142.0K | −6.4%158.0K after | |
| Nov 22, 2023 (view filing) | Nov 20 | 2 days | Edwards MartinDirector | PPurchase | +33.7K | $1.84 | +$62.1K | +30.4%144.8K after |
MORF Morphic Holding, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 15, 2023 (view filing) | Nov 13 | 2 days | Edwards MartinDirector | PPurchase | +2.38K | $20.54 | +$48.8K | New position2.38K after |